Business Update

Enzon receives U.S. FDA clearance of HIF-1 alpha Investigational New Drug Application

Published in Oncology Business Week, March 4th, 2007

Enzon Pharmaceuticals, Inc. (ENZN) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its HIF-1 alpha (hypoxia-inducible factor 1 alpha) antagonist, a highly-visible, well-validated target in many cancer types, including common solid tumors.

The company plans to initiate a phase I trial in the first half of 2007.

"This marks an important milestone for Enzon as we continue to focus our efforts on important oncology therapies," said Jeffrey Buchalter, chairman and chief executive officer of the company. "The continued advancement of the HIF-1 alpha program demonstrates our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2007-03-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry